Bavarian Nordic Seeks Brazil Approval for Chikungunya Vaccine
COPENHAGEN, Denmark, July 13, 2026 Bavarian Nordic announced that its Brazilian partner Eurofarma has submitted a marketing authorization application...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
COPENHAGEN, Denmark, July 13, 2026 Bavarian Nordic announced that its Brazilian partner Eurofarma has submitted a marketing authorization application...
COPENHAGEN, Denmark, April 16, 2026 Bavarian Nordic A/S has announced that Swissmedic, the Swiss Agency for Therapeutic Products, has...
